The CEO attributes fundraising success during a difficult period to having a 'real asset' in clinical trials. This highlights that in challenging capital markets, investors prioritize tangible progress. A company with a drug candidate in human testing is more attractive than one with a promising but unproven discovery platform.

To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.

In a tough funding market for companies without clinical data, Ikarovec's CEO notes that investors heavily weigh the team's credibility. The combination of his own experience with FDA approvals, a seasoned CSO, and a board with multiple billion-dollar exits is a key factor that resonates with investors.

Ikarovec's CEO, a part-time ophthalmologist, sees patients reject current treatments for geographic atrophy due to high treatment burden and limited benefit. This direct experience validates the market's unmet need, providing a powerful, firsthand perspective that strengthens the company's mission and investor pitch.

Unlike therapies targeting specific gene mutations, Ikarovec is developing a "gene-agnostic" treatment for retinitis pigmentosa. This approach significantly broadens the addressable market by offering a potential solution for a wide swath of patients whose mutations aren't amenable to current or developing therapies.

The focus in advanced therapies has shifted dramatically. While earlier years were about proving clinical and technological efficacy, the current risk-averse funding climate has forced the sector to prioritize commercial viability, scalability, and the industrialization of manufacturing processes to ensure long-term sustainability.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

In today's tightened market, a brilliant scientific platform isn't enough to secure investment. Investors have shifted to a product-focused lens, requiring founders to present a clear, detailed pathway from their idea to an approved drug. This includes defining the unmet medical need and outlining the proposed clinical trial design from day one.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.